"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
| Descriptor ID |
D003362
|
| MeSH Number(s) |
N03.219.151.125
|
| Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 6 | 6 |
| 1998 | 0 | 7 | 7 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 9 | 9 |
| 2001 | 1 | 6 | 7 |
| 2002 | 0 | 7 | 7 |
| 2003 | 0 | 10 | 10 |
| 2004 | 1 | 7 | 8 |
| 2005 | 1 | 10 | 11 |
| 2006 | 0 | 11 | 11 |
| 2007 | 0 | 14 | 14 |
| 2008 | 0 | 11 | 11 |
| 2009 | 0 | 8 | 8 |
| 2010 | 0 | 12 | 12 |
| 2011 | 0 | 10 | 10 |
| 2012 | 0 | 19 | 19 |
| 2013 | 0 | 16 | 16 |
| 2014 | 4 | 10 | 14 |
| 2015 | 3 | 23 | 26 |
| 2016 | 3 | 15 | 18 |
| 2017 | 6 | 15 | 21 |
| 2018 | 4 | 16 | 20 |
| 2019 | 4 | 20 | 24 |
| 2020 | 6 | 20 | 26 |
| 2021 | 4 | 20 | 24 |
| 2022 | 1 | 5 | 6 |
| 2023 | 1 | 7 | 8 |
| 2024 | 8 | 7 | 15 |
| 2025 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
The Optimized Use of a Contact-Free Continuous Monitoring System on Clinical Outcomes During COVID-19. J Patient Saf. 2025 Mar 01; 21(2):106-110.
-
Intraoperative neuromonitoring is not a useful adjunct for Chiari malformation decompressive surgery: a cost-benefit and legal analysis. Childs Nerv Syst. 2025 Jan 31; 41(1):96.
-
Consolidation in an Era of Population Health and Value-Based Care: Implications for Effectiveness, Costs, and Equity. Med Care. 2025 Apr 01; 63(4):267-269.
-
Fish oil lipid emulsion compared with soybean oil lipid emulsion in pediatric patients with parenteral nutrition-associated cholestasis: A cost-effectiveness study. JPEN J Parenter Enteral Nutr. 2025 Feb; 49(2):180-188.
-
Evaluating the impact of a tertiary multidisciplinary meeting in metastatic breast cancer: A prospective study. Breast. 2025 Feb; 79:103861.
-
Economic Value of Bronchoscopy Technologies that Improves Sensitivity for Malignancy for Peripheral Pulmonary Lesions. Ann Am Thorac Soc. 2024 Dec; 21(12):1759-1769.
-
Unmet Need in Non-muscle-invasive Bladder Cancer Failing Bacillus Calmette-Gu?rin Therapy: A Systematic Review and Cost-effectiveness Analyses from the International Bladder Cancer Group. Eur Urol Oncol. 2025 Feb; 8(1):216-229.
-
Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective. Gynecol Oncol. 2025 Jan; 192:24-31.
-
The evolving role of multidisciplinary teams in optimizing non-muscle invasive bladder cancer care. Expert Rev Anticancer Ther. 2024 Dec; 24(12):1203-1208.
-
Cost-effectiveness of radiofrequency ablation versus percutaneous ethanol injection for early hepatocellular carcinoma in a resource-poor setting: a randomized trial. Einstein (Sao Paulo). 2024; 22:eGS0683.